Judge Issues Preliminary Injunction Blocking NIH Indirect Cost Cuts for Research Grants
Imminent risk to clinical trials and medical research "warranted the issuance of a nationwide temporary restraining order to maintain the status quo," the judge wrote.
Based on early Phase I/II data, investigators at Cincinnati Children's are enrolling more patients with a telomere biology disorder and bone marrow failure.
NIH Funding Cuts Threaten Research, Clinical Trials, Precision Oncology Progress, Leaders Say
Premium
Researchers warn NIH divestment from research could hinder progress at a pivotal moment for advances in precision cancer medicine.
Focus on Primary Resistance May Improve KRAS Inhibitor Strategies in Colorectal, Pancreatic Cancer
Premium
The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.
Pacira's Gene Therapy Moving to Phase II After Showing Promise Relieving Knee Osteoarthritis Pain
Premium
PCRX-201 became part of Pacira's portfolio in 2021, but was originally developed at Baylor and then by GQ Bio Therapeutics, which Pacira is acquiring.